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Background: Gelatin tannate is a mixture of tannic acid and gelatin. Tannic acid has astringent 
properties, due to its capacity to form protein–macromolecular complexes, as well as antibacterial 
and antioxidant properties. However, little is known about its anti-inflammatory properties.
Purpose: To evaluate the anti-inflammatory activity of gelatin tannate by quantifying the 
suppression of key molecules produced during inflammatory events in lipopolysaccharide 
(LPS)-stimulated human intestinal cells.
Methods: Intercellular adhesion molecule-1 (ICAM-1) expression was determined by Western 
blot analysis; interleukin-8 (IL-8) and tumor necrosis factor-α (TNF-α) concentrations were 
measured by enzyme-linked immunosorbent assays in Caco-2 cells 24 hours after treatment 
with LPS (1 µg/mL) in presence of different concentrations of gelatin tannate.
Results: ICAM-1 is induced on a wide variety of cells by inflammatory stimuli such as LPS. Our 
results have shown gelatin tannate as a potent inhibitor of ICAM-1 expression in LPS-stimulated 
Caco-2 cells. IL-8 and TNF-α are important inflammatory mediators, recruiting neutrophils and 
T-lymphocytes. Together with LPS, adding gelatin tannate at different concentrations induced 
a dose-dependent inhibition of IL-8 and TNF-α released by Caco-2 cells.
Conclusion: These results suggest that gelatin tannate exerts anti-inflammatory effects by 
inhibiting the specific cytokines and adhesion molecules involved in several inflammatory 
disorders.
Keywords: Caco-2, ICAM-1, IL-8, TNF-α
Introduction
The gastrointestinal tract not only plays an important role in the absorption, digestion, 
and exchange of nutrients, but is also the largest organ in the immune system. Under 
normal conditions, the intestinal immune system is kept in balance, within which 
pro- and anti-inflammatory cells, along with other molecules, are carefully regulated 
to promote a normal host mucosal defense capability without destruction of intestinal 
tissue.1 Dysregulation of this balance could lead to pathologic conditions, such as 
inflammatory bowel conditions characterized by the infiltration of inflammatory cells 
from the blood circulation, including monocytes, lymphocytes and neutrophils.2,3
In response to bacteria, toxins and/or the attachment of antigens, the enterocyte, 
through signal transduction pathways, stimulates the genes necessary to regulate inflam-
matory cytokine transcription and translation.4 The mucosal immune system is the 
central catalyst for intestinal inflammation and injury, with cytokines playing a central 
role in modulating inflammation.5 Cytokines may therefore be a logical therapeutic 
target for inflammatory bowel conditions using specific cytokine inhibitors.
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Whilst they are only secondary metabolites of plants, 
tannins are mostly water-soluble phenolic compounds, and 
are well known antioxidants sourced from medicinal plants, 
foods, and edible fruits. Vegetable tannins have attracted a 
lot of attention in recent years because their multifunctional 
properties are beneficial to human health. Their diverse 
biological properties and potential for disease prevention 
have been demonstrated through various in vitro and in 
vivo assays.6
According to their structure, tannins are categorized 
as falling into three categories: hydrolyzable tannins, con-
densed tannins, or complex tannins.7 Hydrolyzable tannins 
are the esters of 3,4,5-trihydroxybenzoic acid (gallic acid). 
Gallic acid molecules are esterified to a core polyol, and 
the   galloyl groups may be further esterified or oxidatively 
cross-linked to form more complex structures. Gallotannins, 
the polygalloyl esters of glucose, are the simplest hydrolyz-
able tannins. 1,2,3,4,6-penta-O-galloyl-β-D-glucose (PGG) 
is a prototypical gallotannin, and the central compound 
in the biosynthetic pathway of hydrolyzable tannins.8 
Though PGG itself is thought to stimulate the secretion 
of tumor necrosis factor-α (TNF-α) and interleukin-1β 
(IL-1β), which are both proinflammatory cytokines, it can 
also attenuate the stimulating effect of lipopolysaccharide 
(LPS) when treated together; this effect has been tested in 
both in vitro and in vivo models.9 Additionally, PGG is 
believed to suppress the expression of adhesion molecules, 
including intercellular adhesion molecule-1 (ICAM-1) and 
vascular cell adhesion molecule-1 (VCAM-1), induced 
by TNF-α. The expression of TNF-α-induced monocyte 
chemoattractant protein-1 (MCP-1) has also been shown 
to be attenuated by PGG.10
Tannic acid is a polymer of gallic acid molecules and 
glucose, and is hydrolyzed into glucose and gallic or ellagic 
acid units. The natural antioxidant, antimicrobial, and anti-
viral activity of hydrolyzable tannins such as tannic acid and 
epigallocatechin gallate have been reported.11–13
Tannic acid is present in many different plant species and 
foods, and is considered a generally recognized safe (GRAS) 
food substance, as well as an official drug in Europe and 
North America.11,14 As an antioxidant compound, tannic acid 
was shown to inhibit lipid oxidation and radical-mediated 
DNA cleavage by scavenging oxygen and oxygen-derived 
radicals.15,16 In addition, numerous studies have suggested 
that tannic acid has antimicrobial activity against food-
borne pathogens such as Escherichia coli and Listeria 
monocytogenes.17–20 Tannic acid has astringent properties 
due to its ability to form macromolecular complexes with 
the proteins to which it binds by means of hydrogen links. 
Some controlled studies have shown tannins to be effective 
in the treatment of diarrhea, with significantly better results 
than placebo, shortening the duration of the disorder with no 
undesirable effects.21,22 Tannic acids do have several undesir-
able gastrointestinal effects: they induce digestive symptoms 
such as nausea and vomiting whilst inhibiting the absorption 
of iron and other metals. The use of tannin complexes such 
as gelatin tannate (TAN), which is hydrolyzed to gelatin 
and tannic acid upon reaching the intestine, prevents gastric 
lesions caused by tannic acid.
It has been demonstrated recently that TAN, a mixture of 
tannic acid and gelatin, exerts an antidiarrhoeal effect.22 The 
efficacy and safety of a similar compound in the treatment of 
acute diarrhea in pediatric patients were studied by Loeb et al 
where infants aged 3–21 months with acute diarrhea of bacte-
rial and viral origin randomly received either a   tannin-rich 
carob pod powder or an equivalent placebo for up to 6 days. 
Participants given the tannate-containing compound showed 
normalization of defecation, body temperature, and weight, 
and ceased vomiting much earlier than those who received 
placebo.21
The aim of the present study was to evaluate the potential 
anti-inflammatory effect of TAN, through an in vitro model to 
study the immune response of intestinal epithelial cells. The 
expression of some inflammatory mediators such as ICAM-1, 
IL-8 and TNF-α was evaluated in human epithelial colorectal 
adenocarcinoma (Caco-2) cells stimulated with LPS, a major 
structural component of Gram-negative bacteria, known as 
one of the most potent inflammatory mediators in intestinal 
epithelium.
Materials and methods
reagents
Gelatin tannate (Tasectan®; Novintethical Pharma Sagl, 
Lugano, Switzerland) is composed of tannic acid and gelatin. 
The gelatin used in the manufacturing of TAN is a type A 
or acid gelatin with a dissolution pH of 5.5 and a Bloom gel 
strength of 40 to 60 g (viscosity of 27 mPs).
Gelatin is a pure natural protein, easily digested, with 
no cholesterol, odor or flavor. Gelatin contains 84%–90% 
collagen protein, 1%–2% mineral salts, and the rest is water. 
The protein is composed of 18 amino acids (glycine, 25.5%; 
alanine, 8.7%; valine, 2.5%; leucine, 3.2%; isoleucine, 
1.4%; cysteine, 0.1%; methionine, 1%; phenylalanine, 2.2%; 
  proline, 18%; hydroxyproline, 14%; serine, 0.4%; threonine, 
1.9%; tyrosine, 0.5%, aspartic acid, 6.6%; glutamic acid, 
11.4%; arginine, 8.1%, lysine, 4.1%; histidine, 0.8%).
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Cell culture and treatments
Caco-2 cells were maintained in minimum essential medium 
(MEM; Sigma-Aldrich, Milan, Italy), supplemented with 
10% fetal calf serum, 100 U/mL penicillin, and 100 µg/mL 
streptomycin, incubated at 37°C within a humidified 95% air 
and 5% CO2 atmosphere. The medium was changed every 
2 to 3 days.
Caco-2 cells usually reached confluence 3 days after seed-
ing, and differentiated into enterocyte-like cells 18–20 days 
postconfluence. All experiments were carried out in these 
fully differentiated cells.
For experiments, 24 hours before they were required, 
the cells were trypsinized and plated in either 96-well plates 
(for enzyme-linked immunosorbent assay [ELISA] tests) or 
100 mm Petri dishes (for Western blot). Caco-2 cells were 
stimulated or not (untreated controls) with LPS at a con-
centration of 1 µg/mL, used to reproduce the mechanisms 
involved in the pathogenesis of inflammatory processes, in 
the absence or presence of different concentrations of TAN 
(1, 10, and 100 µg/mL). After 24-hours’ incubation, each 
sample was tested for ICAM-1 expression, and for IL-8 and 
TNF-α release.
Western blot analysis
The expression of ICAM-1 was evaluated by Western blot 
  analysis. Briefly, both the untreated and treated Caco-2 cells were 
washed twice with icecold phosphate-buffered saline (PBS) 
and collected with lysing buffer (10 mM   Tris-  hydrochloride 
plus 10 mM potassium chloride, 2 mM magnesium chloride, 
0.6 mM phenylmethylsulfonyl fluoride, and 1% sodium 
dodecyl sulfate, pH 7.4). After cooling for 30 minutes at 0°C, 
the cells were sonicated. A total protein of 20 µg, present in 
the supernatant, was loaded onto each lane and separated by 
4% to 12% Novex Bis-Tris gel electrophoresis (NuPAGE; 
Invitrogen, Milan, Italy). Proteins were then transferred 
into nitrocellulose membranes (Invitrogen) in a wet system. 
Membranes were blocked with Tris-buffered saline contain-
ing 0.1% Tween-20 (TBST) and 5% nonfat dry milk at 4°C 
overnight. Mouse monoclonal anti-ICAM-1 (1:200; Santa 
Cruz Biotechnologies, Santa Cruz, CA), and mouse monoclo-
nal anti-α-tubulin antibodies (1:5000; Sigma-Aldrich) were 
diluted in TBST, and the membranes incubated for 24 hours at 
room temperature. Antibodies were detected with horseradish 
peroxidase-conjugated   secondary antibody, using the enhanced 
SuperSignal® West Pico Chemiluminescent Substrate (Pierce 
Chemical Co, Rockford, IL). Bands were measured densito-
metrically, and their   relative density calculated based on the 
density of the α-tubulin bands in each sample. Values were 
expressed as arbitrary   densitometric units   corresponding to 
signal intensity.
ELISA assay
IL-8 and TNF-α were measured on cell-free supernatants 
collected 24 hours after treatment with specific sandwich 
ELISA (Biotrak, EIA System; Amersham Biosciences, 
  Piscataway, NJ). Cell cultures were carried in triplicate for 
each condition. All assays were performed as specified by the 
kit manufacturer. A standard curve was created for each assay 
using known concentrations of IL-8 or TNF-α as provided in 
the kit. Plates were read at 450 nm using a microplate reader. 
The amount of cytokines was quantified within each super-
natant in duplicate. Results were given as mean (expressed 
in pg/mL) and standard error of the mean (SEM).
MTT assay
The cytotoxic effect of the experimental substance was 
evaluated using a cell viability test based on the cleavage 
of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) by mitochondrial dehydrogenases from 
metabolically active cells. Cellular growth was determined 
using the MTT assay on 96-well microplates. The optical 
density of each well sample was measured with a microplate 
spectrophotometer reader at 550 nm.
Statistical analysis
All statistical analyses were performed with the statistical 
software package SYSTAT (v 9.0; Systat Inc, Evanston, IL). 
Each result was calculated as the mean value and SEM. 
Statistical significances between paired and unpaired values 
were performed using the Student’s t-test. P , 0.05 were 
considered statistically significant.
Results
ICAM-1 expression was analyzed at 24 hours in Caco-2 cells 
treated with LPS (1 µg/mL). Western blot analysis revealed 
no constitutive expression of ICAM-1 protein in Caco-2 cells, 
whereas incubation of cultures with LPS for 24 hours induced 
a strong expression of ICAM-1. Addition of TAN at different 
concentrations together with LPS induced a dose-dependent 
inhibition of ICAM-1 expression (Figure 1). At the highest 
dose, TAN blocked ICAM-1 expression by 69%. TAN did 
not induce ICAM-1 expression as noted by the lack of bands 
in the lane corresponding to the treatment of cells with the 
test product.
The expression of both TNF-α and IL-8 was analyzed 
in Caco-2 cells treated with LPS (1 µg/mL) by ELISA 
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assay at 24 hours. Only a negligible amount of TNF-α 
was produced by unstimulated Caco-2 cells, but TNF-α 
was markedly induced by LPS (Figure 2). TAN   markedly 
inhibited LPS-induced release of TNF-α: at a lower 
concentration (1 µg/mL) there was a very significant 
  inhibition (-35%), that further increased at higher (10 and 
100 µg/mL) concentrations of TAN (-43% and -63% 
respectively) (Figure 2). The effects of TAN on the release 
of IL-8 were also investigated. Very low amounts of IL-8 
were produced by unstimulated cells. By contrast, LPS 
potently induced IL-8, which was markedly decreased by 
TAN in a dose-dependent manner (Figure 3). Inhibition 
of LPS-induced inflammatory mediator expression in 
Caco-2 cells by TAN was not due to TAN cytotoxicity, as 
assessed by MTT assay (Figure 4).
Discussion
Our results suggest that TAN has a remarkable anti-
  inflammatory potential due to its strong ability to inhibit 
inflammatory biomarkers, such as LPS-induced ICAM-1, 
IL-8, and TNF-α in Caco-2 cells.
The intestinal epithelium is able to secrete cytokines and 
other mediators of inflammation, to respond to growth fac-
tors and cytokines released by lymphoid cells, and to express 
integrins and HLA class II molecules, which permits direct 
cell-to-cell communication with inflammatory and immune 
cells.22 Evidence indicates that a dysregulation of intestinal 
mucosal immunity, as often seen in inflammatory bowel con-
ditions, causes an overproduction of inflammatory cytokines 
and the trafficking of catalyst leukocytes into the bowel, thus 
leading to an uncontrolled intestinal inflammation.24
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Figure 1 Effects of TAn on ICAM-1 expression induced by LPS in human Caco-2 cells determined by Western blot analysis.
Notes: Data shows the relative expression (mean + SEM) of ICAM-1 calculated as ADU collected from three independent experiments. *P , 0.05 compared with TAn-
induced ICAM-1.
Abbreviations: ADU, arbitrary densitometric units; ICAM-1, intracellular adhesion molecule-1; LPS, lipopolysaccharide; SEM, standard error of mean; TAn, gelatin tannate.
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Proinflammatory cytokines/chemokines produced in 
the intestine play an important role in the pathogenesis of 
complications of critical illness. One of these, IL-8, has 
been shown to be a particularly potent chemoattractant for 
leukocytes and subsequent inflammation.25 IL-8 initiates the 
acute inflammatory cascade, and is also an early marker of 
the inflammatory process; its expression must be controlled 
to prevent both excessive tissue injury, and damage to local 
and distal organs.26
ICAM-1 is a cytokine-inducible glycoprotein belonging to 
the immunoglobulin supergene family. ICAM-1 is constitu-
tively expressed at low levels on a limited number of cell types, 
including endothelial cells,28,29 but its expression is markedly 
upregulated on a wide variety of cells by inflammatory 
cytokines such as IL-lβ, TNF-α, and interferon-γ (IFN-γ).30,31 
ICAM-1 participates in leucocyte adhesion to activated 
endothelial cells, T cell/antigen-presenting cells, T cell-
to-T cell, and T cell/B cell interactions.32 Several epithe-
lial cell types express ICAM-1, including human colonic 
  adenocarcinoma cell lines and colonic cancer cells in vivo.33 
By downregulating the expression of these molecules on the 
endothelium, their interaction with immune cells will be 
reduced and inflammatory activity diminished. This mecha-
nism of action may be of importance to induce remission in 
inflammatory bowel conditions.
TAN is a mixture of tannic acid and gelatin with antidi-
arrheal effects. TAN also has attributed antibacterial and 
antioxidant properties, representing an advantage in the 
empiric use of conventional antibiotics that can contribute 
to the development of resistance and dysbacteriosis.33,34 
  Additionally, unlike other antidiarrheal agents such as 
loperamide,35 it has no effect upon the central nervous system, 
and no other undesirable effects such as reactive constipation. 
More recently, a study reported no TAN-related undesirable 
effects either during or after treatment of acute diarrhea in 
children with a mean age of 2.5 years (standard deviation, 2.4; 
median, 1.7 years); the product was also well tolerated.22
This study demonstrates that the mixture of tannic acid 
and gelatin acts as a potent inhibitor of ICAM-1 (Figure 1) 
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Figure 2 TnF-α production (mean + SEM) measured in the culture media by 
enzyme-linked immunosorbent assay from Caco-2 cells 24 hours after the addition 
of TAn together with LPS.
Notes: Values are expressed as pg/mL. *P , 0.05 and **P , 0.01; significantly 
different from LPS-treated samples.
Abbreviations:  LPS,  lipopolysaccharide;  SEM,  standard  error  of  mean;  TAn, 
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linked immunosorbent assay from Caco-2 cells 24 hours after the addition of TAn 
together with LPS.
Notes: Values are expressed as pg/mL. *P , 0.05 and **P , 0.01; significantly 
different from LPS-treated samples.
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gene expression whilst also suppressing the production of 
IL-8 (Figure 2) and TNF-α (Figure 3) in human enterocytes 
stimulated with LPS. Previous research has shown that 
these are key mediators in the pathogenesis of inflammatory 
bowel conditions, and that the reduction of these mediators 
has been associated with the amelioration of inflammatory 
conditions.36,37 The present in vitro study suggests that TAN 
contributes to decrease the expression and production of such 
inflammatory mediators in Caco-2 cells. It found, in fact, that 
TAN inhibits ICAM-1 expression in LPS-stimulated cells, and 
that it probably acts at the transcriptional level, as evidenced 
by dose-dependent reductions in its levels of expression.
TAN was also found to decrease the release of IL-8 and 
TNF-α. IL-8 is known to be an important cytokine for con-
trolling leukocyte trafficking, and the recruitment of both 
neutrophils and T lymphocytes. TNF-α is a cytokine involved 
in systemic inflammation, and belongs to a group of cytokines 
that stimulate the acute phase reaction.   Dysregulation of TNF-α 
production has been implicated in a variety of human diseases, 
including inflammatory bowel disease (IBD).38 The treatment 
of IBD has advanced in parallel to the improvement of the 
knowledge of its physiopathology, leading to the development 
of biological therapies. An example of this kind of treatment is 
the use of substances that antagonize TNF-α, such as monoclo-
nal antibodies; several studies have demonstrated that inhibition 
of TNF-α is useful in the treatment of IBD.39,40
It has been reported recently that a member of the tannin 
family, known as PGG, is an effective immunoregulator of 
the LPS-mediated TNF-α response in both human peripheral 
blood mononucleocytes, and in live rats. PGG was shown 
to possess anti-inflammatory properties, even if PGG itself 
stimulated the production of TNF-α and IL-1β.9 Here, we 
demonstrate that TAN exerts its beneficial properties without 
inducing the production of inflammatory mediators.
Conclusion
In summary, the present results suggest that TAN could be 
used not only for its antidiarrheal effect, due to astringent 
properties, but also for the treatment of intestinal disorders 
such as inflammatory bowel conditions where inflammatory 
mediators may play a key role. Our data indicates that TAN 
may be effective, with minimal or no toxicity, in the treat-
ment of intestinal inflammatory conditions.
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